Roche Holding | ROG - Selling And Administration Expenses




Roche Holding reported CHF3.61B in Selling and Administration Expenses for its fiscal semester ending in December of 2024.

Selling And Administration Expenses Change Date
AbbVie USD 3.86B 350M Dec/2024
Alcon AG USD 809M 28M Sep/2024
Almirall EUR -50222000 162.22M Jun/2024
Amgen USD 1.82B 194M Dec/2024
AstraZeneca USD 5.55B 307M Dec/2024
Bayer EUR 3.72B 325M Sep/2024
Biogen USD 588.4M 34.6M Sep/2024
Bristol-Myers Squibb USD 2.14B 153M Dec/2024
Eli Lilly USD 2.42B 324.7M Dec/2024
Fresenius EUR 701M 102M Sep/2024
Fresenius Medical Care EUR 756M 15.47M Sep/2024
Galapagos EUR 29.26M 3.88M Sep/2024
Genmab DKK 865M 29M Sep/2024
Gilead Sciences USD 1.4B 28M Sep/2024
GlaxoSmithKline GBP 2.66B 1.14B Dec/2024
GRIFOLS EUR 319.42M 19.74M Sep/2024
Hikma Pharmaceutical USD 280M 4M Jun/2024
Merck EUR 1.41B 72M Sep/2024
Merck USD 2.86B 207M Dec/2024
Novartis USD 3.5B 368M Dec/2024
Orion EUR 85.8M 5.6M Sep/2024
Pfizer USD 4.28B 1.06B Dec/2024
Philips EUR 1.23B 59M Sep/2024
Recordati EUR 149.34M 15.49M Sep/2024
Regeneron Pharmaceuticals USD 792.2M 77.8M Dec/2024
Roche Holding CHF 3.61B 381M Dec/2024
Sanofi EUR 2.68B 26M Sep/2024
UCB EUR 533M 434M Jun/2024